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ABSTRACT: The utility of low sample volume in vitro diagnostic
(IVDr) proton nuclear magnetic resonance (1H NMR) spectro-
scopic experiments on blood plasma for information recovery from
limited availability or high value samples was exemplified using
plasma from patients with SARS-CoV-2 infection and normal
controls. 1H NMR spectra were obtained using solvent-suppressed
1D, spin−echo (CPMG), and 2-dimensional J-resolved (JRES)
spectroscopy using both 3 mm outer diameter SampleJet NMR
tubes (100 μL plasma) and 5 mm SampleJet NMR tubes (300 μL
plasma) under in vitro diagnostic conditions. We noted near
identical diagnostic models in both standard and low volume IVDr
lipoprotein analysis (measuring 112 lipoprotein parameters) with a
comparison of the two tubes yielding R2 values ranging between 0.82 and 0.99 for the 40 paired lipoprotein parameters samples.
Lipoprotein measurements for the 3 mm tubes were achieved without time penalty over the 5 mm tubes as defined by biomarker
recovery for SARS-CoV-2. Overall, biomarker pattern recovery for the lipoproteins was extremely similar, but there were some small
positive offsets in the linear equations for several variables due to small shimming artifacts, but there was minimal degradation of the
biological information. For the standard untargeted 1D, CPMG, and JRES NMR experiments on the same samples, the reduced
signal-to-noise was more constraining and required greater scanning times to achieve similar differential diagnostic performance (15
min per sample per experiment for 3 mm 1D and CPMG, compared to 4 min for the 5 mm tubes). We conclude that the 3 mm
IVDr method is fit-for-purpose for quantitative lipoprotein measurements, allowing the preparation of smaller volumes for high value
or limited volume samples that is common in clinical studies. If there are no analytical time constraints, the lower volume
experiments are equally informative for untargeted profiling.
KEYWORDS: blood plasma, 1H NMR spectroscopy, IVDr, miniaturization, metabolic phenotyping, biomarkers, low volume,
3 mm NMR tubes, SARS-CoV-2, spin−echo, J-resolved
■ INTRODUCTION
High field proton NMR spectroscopy of biofluids coupled with
pattern recognition methods have been applied extensively to
problems in metabolic biochemistry, toxicology, and exper-
imental diagnostics for more than three decades.1−4 More
recently, data analytic procedures such as curve and regression
fitting have been used to extract quantitative lipoprotein and
metabolic data from 1-dimensional blood plasma and urine
spectra.5−7 The mainstay of most biofluid NMR studies is the
standard 5 mm outer diameter liquid state NMR tubes (with 5
mm NMR probes) used in the vast majority of all high-
resolution chemical and biochemical experiments. A range of
tube sizes is also widely available, for example 1 mm to 10 mm
for high resolution studies and 15 mm 25 mm tubes for wide-
bore NMR applications. Each tube size has been optimized for a
particular sample volume range and there are sensitivity
consequences for using smaller sample volumes at the same
sample concentration because the absolute analyte mass in the
probe is reduced proportionately.
Of note, the signal-to-noise ratio (S/N) in an NMR
experiment is proportional to the absolute analyte mass in the
receiver coil; halving this will require a quadruple number of
scans to obtain the same S/N in an identical probe with identical
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filling factor (the % of the receiver coil containing the analytes).8
This can result in severe spectral acquisition time penalties for
low volume samples or compromised S/N ratios with weaker
diagnostic performance. It is rare to have volume limitations for
urine samples even in small animal studies.6 However, blood
plasma or serum samples are commonly available in limited
amounts, such as those on small animals or infants, where it
would be unethical to withdraw large amounts of blood, or in
situations where the samples that are available are needed for
multiple parallel metabolic studies involving multiple technol-
ogies. The latter applies to systemic metabolic studies on
COVID-19, where attempts to uncover the complex metabolic
sequelae via multiple orthogonal technologies often applied on
the same samples,9 leading to analytical priority decisions that
may reduce the number of analytical options per sample. 1H
NMR spectroscopy of biofluids for in vitro diagnostics in
standard 5 mm tubes requires ca. 0.3 mL of sample.10,11
The standard IVDr NMR methods for blood plasma
lipoprotein measurements utilize 5 mm tubes with a minimal
sample requirement of 300 μL (plus 300 μL buffer) as
determined by a validated IVDr protocol,12 while mass
spectrometry requires typically 10−30 μL per assay.13−15 Any
reduction in NMR preparative volumes will therefore provide
more opportunities for complementary analytical coverage of
the same sample using additional spectroscopic assays. Here the
use of 100 μL plasma in 3 mm SampleJet tubes was investigated
using a modified IVDr method and longer scanning times and
compared with standard IVDr methods in 5 mm SampleJet
tubes using a cohort of control, SARS-CoV-2 positive patients,
and SARS-CoV-2 negative patients.
■ MATERIALS AND METHODS
Patient Enrolment and Sample Collection
Blood plasma and serum samples were collected from a cohort of
adult individuals in a study initiated at Fiona Stanley Hospital by
the Covid Research Response team (https://research-au.net/
covid-research-response/) as part of the International Severe
Acute Respiratory and Emerging Infection Consortium
(ISARIC)/ World Health Organisation (WHO) pandemic
trail framework (SMHSResearch Governance Office PRN:3976
andMurdoch University Ethics no. 2020/052). Three groups of
participants were recruited: (i) patients who presented with
SARS-CoV-2 disease symptoms and subsequently tested
positive for SARS-CoV-2 infection from upper and/or lower
respiratory tract swabs by RT-PCR (n = 9 participants); (ii)
blood samples from patients with SARS-CoV-2 disease
symptoms and who had tested negative by RT-PCR (n = 27
participants); and (iii) healthy controls with no respiratory
symptoms (n = 4 participants) who were enrolled as volunteers,
according to Murdoch University Ethics no. 2020/053. The
demographic data are shown in Table S1.
Sample Preparation for NMR Analysis
Plasma samples were centrifuged and processed according to a
standard protocol.10,11 Prior to NMR analysis, frozen plasma
samples were thawed at 20 °C for 30 min and centrifuged for 10
min at 13 000g at 4 °C. Plasma samples were prepared using
both 5 mm SampleJet NMR tubes, following the recommended
procedures for in vitro analytical and diagnostics procedures,12
and 3 mm SampleJet NMR tubes. For the standard sample
preparation for 5 mm NMR tubes, each aliquot of 300 μL of
plasma was mixed with 300 μL phosphate buffer (75 mM
Na2HPO4, 2 mM NaN3, 4.6 mM sodium trimethylsilyl
propionate-[2,2,3,3−2H4] (TSP) in 80% D2O, pH 7.4 ±
0.1),11 mixed and spun for 5 s to ensure all liquid is at the
bottom of the tube and transferred to a 5 mm SampleJet tube.
For the sample preparation using 3 mm SampleJet NMR tubes,
each aliquot of 100 μL of plasma was mixed with 100 μL
phosphate buffer, mixed and spun for 5 s and 180 μL was
transferred to a 3 mm tube for analyses. The 3 mm SampleJet
NMR tubes require less than a third of the sample volume
compared to the 5 mm SampleJet NMR tubes.
1H NMR Spectroscopy Data Acquisition and Processing
Parameters
NMR spectroscopic analyses were performed on a 600 MHz
Bruker Avance III HD spectrometer equipped with a 5 mm BBI
probe and fitted with the Bruker SampleJet robot cooling system
set to 5 °C. A full quantitative calibration was completed prior to
the analysis using a previously described protocol.11 All
experiments were completed using the Bruker in vitro
diagnostics research (IVDr) methods.16 For samples prepared
in both 3 mm SampleJet and 5 mm SampleJet NMR tubes, three
experiments were carried out in automationmode, amounting to
a total of 12.5 min acquisition time per sample: standard 1D
experiment with solvent presaturation with gradient (32 scans,
96K data points, spectral width of 30 ppm), a Carr−Purcell−
Meiboom−Gill (CPMG) spin−echo experiment (32 scans, 72K
data points, spectral width of 20 ppm) and a 2-dimensional J-
resolved experiment (40 t1 increments with 2 scans each). In
addition, for the samples prepared in both 3 mm SampleJet
NMR tubes, three further experiments were completed using
higher scan option for each experiment amounting to a total
acquisition time of 38 min per sample: standard 1D experiment
with solvent presaturation (128 scans, 96K data points, spectral
width of 30 ppm), a Carr−Purcell−Meiboom−Gill (CPMG)
spin−echo experiment (128 scans, 72K data points, spectral
width of 20 ppm) and a 2-dimensional J-resolved experiment
(40 t1 increments with 4 scans each). Data were processed in
automation using Bruker Topspin 3.6.2 and ICON NMR to
achieve phasing and baseline correction.17
A total of 112 lipoprotein parameters for each sample were
generated using the Bruker IVDr Lipoprotein Subclass Analysis
(B.I.-LISA) method by mathematically interrogating and
quantifying the −(CH2)n at δ = 1.25 and −CH3 at δ = 0.80
peaks of the 1D spectrum after normalization to the Bruker
QuantRef manager within Topspin using a PLS-2 regression
model.12 The lipoprotein data describe chemical components of
cholesterol, free cholesterol, phospholipids, triglycerides,
Apolipoproteins A1/A2/B100 and the B100/A1 ratio in
different density classes: high-density lipoprotein (HDL, density
1.063−1.210 kg/L), intermediate-density lipoprotein (IDL,
density 1.006−1.019 kg/L) low-density lipoprotein (LDL,
density 1.09−1.63 kg/L), and very low-density lipoprotein
(VLDL, 0.950−1.006 kg/L). Themain lipoprotein classes HDL,
LDL, VLDL were subdivided into different density subclasses
(LDL-1:1.019−1.031 kg/L, LDL-2:1.031−1.034 kg/L, LDL-
3:1.034−1.037 kg/L, LDL-4:1.037−1.040 kg/L, LDL-5:1.040−
1.044 kg/L, LDL-6:1.044−1.063 kg/L), and the HDL
subfractions into 4 different density classes (HDL-1 1.063−
1.100 kg/L, HDL-2 1.100−1.125 kg/L, HDL-3 1.125−1.175
kg/L, and HDL-4 1.175−1.210 kg/L), the VLDL subfractions
divided into 5 different density classes. A list of the 112
lipoprotein subfractions and parameter annotations is provided
in Table S2.
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Figure 1. PCA of lipoprotein concentrations using 3 mm and 5 mm SampleJet NMR tubes: (A) PCA scores plot showing both 3 mm and 5 mm
SampleJet NMR tubes were substantially similar. PCA loadings plots for the (B) 5 mm NMR SampleJet tubes only; and (C) 3 mm NMR SampleJet
tubes only.
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NMR Data Analysis
The 1D and CPMG NMR spectral data sets were referenced to
glucose at δ = 5.25 using open source MetaboM8 software
packages available from GitHub (github.com/tkimhofer/
metabom8, version 0.1)18 and corrected for baseline offset.
Spectral regions corresponding to the residual water resonance
signal (δ = 4.60−4.85) and those predominantly noise (δ < 0.25
and δ > 9.5) were excluded from analyses. The remaining
spectral segments were normalized using a probabilistic quotient
method,19 mean-centered and scaled to unit-variance prior to
multivariate modeling. Principal component analysis (PCA) was
used to describe the underlying composition in quantitative
lipoprotein, 1D and CMPG spectral data sets and to identify the
clustering of healthy controls, SARS-CoV-2 positive, and SARS-
CoV-2 negative individuals.
■ RESULTS AND DISCUSSION
Quantitative Comparison of 5 mm and 3 mm Lipoprotein
Fractions
One of the real-world problems in studying complex emergent
diseases such as SARS-CoV-2 is that patient sampling is often
sparse or incomplete and multiple subsamples are needed to
cover a large number of biochemical tests and different mass
spectrometric assays. This problem is also applicable where
there are limited sample volumes, including studies on children
and babies. Here the use of reduced sample volumes was
investigated using 3 mm SampleJet NMR tubes (100 μL of
plasma required) compared against the standard 5 mm
SampleJet tube method (300 μL) for blood plasma with the
standard lipoprotein IVDr quantification employing three
different study cohortsSARS-CoV-2 positive, SARS-CoV-2
negative, and healthy control samples.
IVDr methods extracted 112 lipoprotein parameters from the
1D spectra of the same samples either in 3 mm or 5 mm tubes,
both obtained using 32 scans (4 min experiment). The overall
PCA mapping of a mixture of the different patient and sample
tubes with the different volumes are shown in Figure 1 with
identical biological samples connected by dotted lines. The
overall statistical distribution of the samples was maintained, i.e.,
multivariate biological variation exceeded the analytical
variation and that thus the outputs of the two analytical
procedures were substantially equivalent. However, some minor
discrepancies for some samples were observed due to differential
field inhomogeneities (shimming artifacts) that slightly
influence the quantitative output of the IVDr fitting algorithms
for some parameters. The PCA loading plots for the samples
prepared in 5 mm and 3 mm SampleJet NMR tubes are nearly
identical (Figures 1B and 1C), indicating equivalent biomarker
information recovery. A detailed biological description of the
meaning of these parameters in relation to the complex
biochemical of SARS-CoV-2 positivity is reported elsewhere.9
OPLS-DA was applied to the 5 mm and 3 mm lipoprotein data
sets to compare the healthy controls and the SARS-CoV-2
positive patients. The different size tubes both yielded an
AUROC of 1.0 with the coefficient plots yielding the same
lipoprotein parameters driving the SARS-CoV-2 signature
(Figure S1).
The quantitative relationships between the different sample
volumes is illustrated in Figure 2 for the main six lipoprotein
fractions. In all cases, there was a high degree of linearity with
exceptionally high coefficients of determination (R2 in the range
Figure 2. Comparison of lipoprotein concentrations for the six main fractions using 5 mm SampleJet NMR tubes and 3 mm SampleJet NMR tube by
the Bruker quantitative IVDrmethod. Total triglyceride; total cholesterol; LDL-cholesterol; HDL-cholesterol; Apolipoprotein A1; and apolipoprotein
A2. The fit equation and R2 are shown for each lipoprotein parameter.
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Table 1. Quantitative Comparison of 5 mm and 3 mm Lipoprotein Fractions, Showing the Fit Equation and R2 for Each
Fraction between Identical Paired Samples in 5 mm versus 3 mm NMR Tubes (n = 40)
lipoprotein fraction fit equation R2
Triglyceride y = 1.23x − 16.32 0.98
Cholesterol y = 1.02x + 1.60 0.98
LDL-Cholesterol y = 0.98x + 8.35 0.97
HDL-Cholesterol y = 1.05x − 1.54 0.98
Apo-A1 y = 1.06x − 2.98 0.98
Apo-A2 y = 1.05x − 0.39 0.98
Apo-B100 y = 1.00x + 5.15 0.95
LDL-Chol/HDL-Chol y = 1.00x + 0.09 0.98
Apo-B100/Apo-A1 y = 1.00x + 0.01 0.98
Total particle number y = 1.00x + 93.52 0.95
VLDL particle number y = 1.11x − 13.84 0.99
IDL particle number y = 1.04x + 6.38 0.92
LDL particle number y = 0.97x + 106.17 0.96
LDL-1 particle number y = 1.07x − 29.44 0.93
LDL-2 particle number y = 1.02x + 3.27 0.92
LDL-3 particle number y = 1.03x + 3.01 0.95
LDL-4 particle number y = 0.94x + 26.57 0.96
LDL-5 particle number y = 0.97x + 40.30 0.85
LDL-6 particle number y = 1.16x − 22.01 0.93
Triglycerides VLDL y = 1.74x − 2.93 0.98
Triglycerides IDL y = 1.22x − 0.87 0.99
Triglycerides LDL y = 1.03x + 0.82 0.91
Triglycerides HDL y = 1.14x − 0.55 0.93
Cholesterol VLDL y = 1.13x − 2.86 0.99
Cholesterol IDL y = 1.14x − 0.19 0.95
Cholesterol LDL y = 0.98x + 8.54 0.97
Cholesterol HDL y = 1.05x − 1.54 0.98
Free cholesterol VLDL y = 1.09x − 0.51 0.99
Free cholesterol IDL y = 1.17x − 0.20 0.95
Free cholesterol LDL y = 1.00x + 2.28 0.96
Free cholesterol HDL y = 1.09x + 0.29 0.96
VLDL phospholipids y = 1.07x − 0.10 0.99
IDL phospholipids y = 1.16x − 0.32 0.98
LDL phospholipids y = 0.98x + 3.31 0.97
HDL phospholipids y = 1.07x − 3.50 0.99
Apo-A1 HDL y = 1.06x − 3.32 0.97
Apo-A2 HDL y = 1.05x − 0.50 0.97
Apo-B VLDL y = 1.11x − 0.76 0.99
Apo-B IDL y = 1.04x + 0.35 0.92
Apo-B LDL y = 0.97x + 5.39 0.96
Triglycerides VLDL-1 y = 1.18x + 1.71 0.95
Triglycerides VLDL-2 y = 1.15x − 0.67 0.99
Triglycerides VLDL-3 y = 1.20x − 1.58 0.98
Triglycerides VLDL-4 y = 1.13x − 0.51 0.98
Triglycerides VLDL-5 y = 1.04x − 0.04 0.95
Cholesterol VLDL-1 y = 1.16x − 0.59 0.97
Cholesterol VLDL-2 y = 1.15x − 0.57 0.99
Cholesterol VLDL-3 y = 1.16x − 0.44 0.97
Cholesterol VLDL-4 y = 1.01x + 0.01 0.96
Cholesterol VLDL-5 y = 1.09x − 0.30 0.92
Free cholesterol VLDL-1 y = 1.14x − 0.04 0.97
Free cholesterol VLDL-2 y = 1.18x − 0.30 0.98
Free cholesterol VLDL-3 y = 1.18x − 0.17 0.99
Free cholesterol VLDL-4 y = 1.05x + 0.04 0.97
Free cholesterol VLDL-5 y = 0.93x − 0.71 0.92
Phospholipids VLDL-1 y = 1.16x + 0.01 0.96
Phospholipids VLDL-2 y = 1.12x − 0.24 0.99
lipoprotein fraction fit equation R2
Phospholipids VLDL-3 y = 1.15x − 0.31 0.98
Phospholipids VLDL-4 y = 1.12x − 0.43 0.98
Phospholipids VLDL-5 y = 1.09x − 0.18 0.94
Triglycerides LDL-1 y = 1.09x − 0.71 0.91
Triglycerides LDL-2 y = 0.95x + 0.16 0.93
Triglycerides LDL-3 y = 0.99x + 0.01 0.99
Triglycerides LDL-4 y = 0.99x + 0.15 0.94
Triglycerides LDL-5 y = 1.02x + 0.21 0.90
Triglycerides LDL-6 y = 1.12x − 0.28 0.96
Cholesterol LDL-1 y = 1.08x − 3.62 0.94
Cholesterol LDL-2 y = 1.02x + 0.17 0.94
Cholesterol LDL-3 y = 1.01x + 0.52 0.95
Cholesterol LDL-4 y = 0.95x + 2.02 0.96
Cholesterol LDL-5 y = 0.97x + 3.09 0.87
Cholesterol LDL-6 y = 1.10x − 0.12 0.93
Free cholesterol LDL-1 y = 1.09x − 0.79 0.95
Free cholesterol LDL-2 y = 0.99x + 0.42 0.92
Free cholesterol LDL-3 y = 1.02x + 0.26 0.94
Free cholesterol LDL-4 y = 0.96x + 0.75 0.93
Free cholesterol LDL-5 y = 0.95x + 1.11 0.82
Free cholesterol LDL-6 y = 1.15x + 0.22 0.88
Phospholipids LDL-1 y = 1.09x − 2.22 0.93
Phospholipids LDL-2 y = 1.02x − 0.10 0.94
Phospholipids LDL-3 y = 1.03x + 0.08 0.94
Phospholipids LDL-4 y = 0.95x + 1.05 0.96
Phospholipids LDL-5 y = 0.95x + 1.81 0.87
Phospholipids LDL-6 y = 1.12x − 0.44 0.92
Apo-B LDL-1 y = 1.07x − 1.62 0.93
Apo-B LDL-2 y = 1.02x + 0.18 0.92
Apo-B LDL-3 y = 1.03x + 0.16 0.95
Apo-B LDL-4 y = 0.94x + 1.46 0.96
Apo-B LDL-5 y = 0.97x + 2.21 0.85
Apo-B LDL-6 y = 1.57x − 1.21 0.93
Triglycerides HDL-1 y = 0.95x + 0.68 0.85
Triglycerides HDL-2 y = 1.03x + 0.23 0.89
Triglycerides HDL-3 y = 1.14x − 0.09 0.92
Triglycerides HDL-4 y = 1.09x − 0.22 0.99
Cholesterol HDL-1 y = 1.05x + 0.45 0.98
Cholesterol HDL-2 y = 1.00x + 0.71 0.96
Cholesterol HDL-3 y = 1.04x + 0.04 0.98
Cholesterol HDL-4 y = 0.96x − 0.19 0.95
Free cholesterol HDL-1 y = 1.08x + 0.44 0.97
Free cholesterol HDL-2 y = 1.07x + 0.20 0.96
Free cholesterol HDL-3 y = 1.09x + 0.18 0.96
Free cholesterol HDL-4 y = 1.03x + 0.20 0.92
Phospholipids HDL-1 y = 1.05x + 0.30 0.98
Phospholipids HDL-2 y = 1.00x + 1.01 0.96
Phospholipids HDL-3 y = 1.06x + 0.31 0.98
Phospholipids HDL-4 y = 0.98x − 0.53 0.97
Apo-A1 HDL-1 y = 1.05x + 0.30 0.98
Apo-A1 HDL-2 y = 1.04x − 0.09 0.98
Apo-A1 HDL-3 y = 1.05x − 0.11 0.98
Apo-A1 HDL-4 y = 0.96x + 0.98 0.96
Apo-A2 HDL-1 y = 1.06x + 0.12 0.98
Apo-A2 HDL-2 y = 1.02x + 0.30 0.95
Apo-A2 HDL-3 y = 1.06x + 0.19 0.96
Apo-A2 HDL-4 y = 0.99x − 0.19 0.97
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0.82 to 0.99). However, there were some small positive offsets in
the linear equations for several metabolites in certain compart-
ments, e.g., LDL cholesterol and total triglycerides, although
these need to be considered in relation to the overall magnitude
of the lipoprotein concentration (Figure 2).
Individual linear equations for all 112 lipoproteins are listed in
Table 1, with all but seven lipoprotein parameters (cholesterol
LDL-5, free cholesterol LDL-6, free cholesterol LDL-5,
phospholipids LDL-5, Apo-B LDL-5, triglycerides HDL-1, and
triglycerides HDL-2) showing R2 values of <0.9, indicating the 3
mm tubes can be used with confidence for all the measured IVDr
lipoprotein parameters. The R2 values and the calculated linear
equations relating the variables for 3 mm and 5 mm tubes are
shown in Table 1.
1D, CPMG, and JRES Spectral Data
Examination of the 1D and CPMG spectral data sets indicated
that the signal-to-noise ratio of the 3 mm SampleJet NMR tubes
was 2.8 times lower than that of the 5 mm, when 32 scans were
used, which is due to the filling-effect of the 3 mm tubes in the 5
mm NMR probe volume. In particular, the metabolite signals at
the aromatic regions were largely not detectable for the 3 mm
NMR tubes with 32 scans (Figure S2). However, we expect that
improved performance with a dedicated 3 mm NMR probe will
be achievable. It was found that at least 128 scans for the 3 mm
SampleJet NMR tubes was required in order for the aromatic
peaks and some of the lower concentration metabolites to have
sufficient signal-to-noise to be comparable to the standard 5 mm
IVDr 32 scan method. For the JRES spectral data sets at least 4
scans are required in order to gain sufficient peak information
(Figure S3).
PCAmodels were constructed for the 1D and CPMG spectral
data sets separately, using healthy controls, SARS-CoV-2
negative, and the SARS-Cov-2 positive patients. Both the
standard 32 scans (5 mm NMR tubes) and 128 scans (3 mm
NMR tubes) showed highly comparable results for the 1D
Figure 3. PCA scores and loading plots of the 1D spectral data for 5mm and 3mmSampleJet NMR analyses on 32 and 128 scans, respectively. (A) The
PCA model for healthy controls, SARS-CoV-2 positive, and SARS-CoV-2 negative samples 1D spectra using 5 mm SampleJet NMR tubes with 32
scans. The ellipse indicates the boundary of the Hotelling’s T2 statistic (α = 0.95), which can be interpreted as a multivariate confidence interval; (B)
the corresponding loadings plot for principal component 1 (PC1); and (C) principal component 2 (PC2). (D) The PCA model for healthy control,
SARS-CoV-2 positive, and SARS-CoV-2 negative samples 1D spectra in 3 mm SampleJet NMR tubes using 128 scans; (E) the corresponding loadings
for PC1; and (F) PC2.
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(Figure 3) and CPMG (Figure 4) spectral data sets, but this was
achieved at the cost of an approximately 4-fold increase in the
total experimental time for each sample in the 3mmNMR tubes.
When the PCAmodel was constructed for the CPMG spectral
data set using 32 scans in the 3mmNMR tubes, it was found that
the PCA scores plot show clustering patterns that were similar to
those seen in both the 5mm tubes (32 scans) and the 3mm (128
scans) SampleJet NMR tubes (Figure S4A). However, the
loading plots clearly show that the clustering was dominated by
the aliphatic molecules in the 3 mm NMR tubes with 32 scans
(Figures S4B and S4C). The difference from the aromatic
regions among the SARS-CoV-2 positive patients compared to
the healthy and SARS-CoV-2 negative patients were not
recovered using the 3 mm NMR tube with 32 scans when
compared to the 5 mm NMR tubes using 32 scans (Figure S4D
and S4E). This finding confirms that higher scan numbers are
required for the 3 mm SampleJet NMR tubes in order to get the
same level of metabolite signals information recovery from the
healthy controls, SARS-CoV-2 positive and SARS-CoV-2
negative patients.
We conclude that all NMR experiments applied in this test
series give substantially equivalent, differential diagnostic
information for SARS-CoV-19 positive patient samples. The
IVDr lipoprotein analysis is highly efficient and results in
excellent quantitative agreement between the different sample
volumes with no time penalty. However, the untargeted analysis
is more sensitive to the reduced S/N in the smaller volumeNMR
tubes and therefore requires greater spectral accumulation time
to recover similar metabolic biomarkers. We recommend that
for clinical studies involving small numbers of samples and with
limited sample volume, it would be feasible to adopt untargeted
analysis using 3 mm NMR tubes with a higher scan number.
Figure 4. PCA scores and loading plots of the CPMG spectral data for 5mm and 3mmSampleJet NMR analyses on 32 and 128 scans, respectively. (A)
The PCA model for healthy controls, SARS-CoV-2 positive, and SARS-CoV-2 negative samples CPMG spectra in 5 mm SampleJet NMR tubes using
32 scans. The ellipse indicates the boundary of the Hotelling’s T2 statistic (α = 0.95), which can be interpreted as a multivariate confidence interval;
(B) the corresponding loadings plot for PC1; and (C) PC2. (D) The PCA model for healthy controls, SARS-CoV-2 positive, and SARS-CoV-2
negative samples CPMG spectra in 3 mm SampleJet NMR tubes using 128 scans; (E) the corresponding loadings for PC1; and (F) PC2.
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